A Study of LY2940680 in Healthy Participants

Healthy Participants Clinical Trial

Official title:

A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01681186
• Other study ID #: 14893
• Secondary ID: I4J-MC-HHBG
• Status: Completed
• Phase: Phase 1
• Start date: September 2012
• Est. completion date: December 2012

Study information

• Verified date: September 2019
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy sterile males or surgically sterile females or postmenopausal females, as determined by medical history and physical examination

• Body mass index of 18.5 to 32.0 kilograms per meter square (kg/m^2)

• Have clinical laboratory test results within normal reference range

• Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site

• Prepared to eat an entire high fat breakfast

Exclusion Criteria:

• Are currently enrolled in, have completed or discontinued within the last 30 days from a clinical trial involving an investigational product

• Have known allergies to LY2940680, related compounds or any components of the formulation, or known allergies to lansoprazole (Part B only)

• Have previously completed or withdrawn from this study or any other study investigating LY2940680, and have previously received the investigational product. Participants in Part A are not allowed to participate in Part B

• Have an abnormality in the 12-lead electrocardiogram (ECG)

• Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data (cholecystectomy or appendectomy are allowed if surgery at least 6 months prior to screening)

• Regularly use known drugs of abuse and/or show positive findings on urinary drug screening

• Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies

• Show evidence of hepatitis C and/or positive hepatitis C antibody

• Show evidence of hepatitis B and/or positive hepatitis B surface antigen

• Have used or intend to use over-the-counter or prescription medication within 14 days prior to dosing or during the study. Exception: participants may continue hormone replacement therapy (HRT; estrogen)

• Use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice, Seville oranges, or Starfruit within 7 days prior to dosing or during the study

Related Conditions & MeSH terms

• Healthy Participants

Intervention

Drug:
• LY2940680 Capsule(s) (Reference)
Administered orally as a capsule(s)
• LY2940680 Tablet (Test)
Administered orally as a tablet
• Lansoprazole
Administered orally as a capsule
• Placebo Capsule(s)
Administered orally as a capsule(s)

Locations

Country	Name	City	State
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs	Data presented are the number of participants with AEs or any serious AEs (SAEs) regardless of causality. A summary of non-serious AEs is located in the Reported Adverse Events section.	Baseline through study completion (up to 4 weeks in Part A and 8 weeks in Part B)
Primary	Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation	The Cmax of 100-milligram (mg) LY2940680 capsule (reference formulation) and 100-mg LY2940680 tablet (test formulation) in fasted and fed state, and with lansoprazole during Part B of the study.	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours after administration of study drug
Secondary	Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)	The Cmax of LY2940680 during Part A of the study was reported.	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Secondary	Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)	Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Secondary	Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)	Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Secondary	Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]	Part A: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration [AUC(0-tlast)]	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Secondary	Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]	Part B: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration [AUC(0-tlast)]	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Secondary	Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-8)]	Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-8)]	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Secondary	Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-8)]	Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-8)]	Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug